Valneva Se (VALN) has released an update.
Valneva SE has reported encouraging Phase 3 data for its single-shot chikungunya vaccine, VLA1553, confirming high immunogenicity and safety in adolescents, and potentially extending its use to this age group. The company, which already has FDA approval for the vaccine in adults, is also aiming for licensure in Brazil to address the high morbidity caused by the chikungunya virus. Valneva’s efforts are supported by multiple regulatory reviews and a collaboration with Instituto Butantan in Brazil, funded by CEPI and the EU’s Horizon 2020 program.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.